Activating mutations of the EGFR gene are found in a subset of lung carcinomas (10% of adenocarcinomas in the Caucasian population) and define a subpopulation of cancers that can benefit from oral EGFR tyrosine kinase inhibitors (TKIs) [4]. The gene discussed is EGFR; the disease is lung carcinoma.